Umbilical Cord Blood Transplant for Hematological Malignancies

Completed · Phase 1

Conditions studied: CML, AML, MDS, ALL, NHL, Multiple Myeloma, Hodgkin's Disease

In brief

This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant. In this study, subjects will undergo a Stem Cell Transplant using Cord Blood. Part of the cord blood will be used for the Stem Cell Transplant and part of the cord blood will be sent to a laboratory in order to grow the T cells (from the cord blood) and increase the activity of the cord blood T cells. The purpose of this part of the study is to see if it is safe to give study subjects activated T cells made from a small portion of their donor UCB unit immediately after the UCB transplant. Activated T cells have been used safely in stem cell transplantation studies in the past, but they have never been studied UCB transplantation.

Key facts

Study ID

NCT00891592

Run by

University of Pennsylvania

People needed

5

Starts

2009-01-01

Expected to finish

2016-05-01

Last updated by the study team

2016-08-19

Who can join

Age: 21 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Subject is pregnant or lactating.
• Subject has an uncontrolled infection.
• Subject has an active or untreated disease involving the central nervous system.
• Subject has an active or uncontrolled medical condition that would preclude participation in the protocol.

Where it is running

• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.